Charles River Laboratories International Inc (CRL)
Health Services • Health Care
July 15, 2026 Charles River Laboratories Prepares for Second-Quarter 2026 Earnings Release Charles River Laboratories is set to release its second-quarter 2026 earnings on August 5, before market opens. A conference call will follow for detailed insights on performance and strategy.
July 13, 2026 Charles River Laboratories Partners with Arovella Therapeutics to Propel Cancer Treatment Innovations Charles River Laboratories partners with Arovella Therapeutics to enhance cancer treatment development through Next Generation Sequencing services. This collaboration aims to support Arovella's iNKT cell therapy platform, improving safety and efficiency in manufacturing.
June 18, 2026 Charles River Laboratories Partners with Lilly TuneLab to Enhance AI/ML Drug Discovery Charles River Laboratories has partnered with Lilly TuneLab to enhance AI/ML drug discovery. This collaboration aims to expedite drug development through improved nonclinical testing and innovative therapeutic approaches, fostering biotech innovation.
June 01, 2026 Charles River Laboratories Set to Showcase Strategic Insights at Upcoming Conferences Charles River Laboratories will present its strategic insights at the William Blair and Jefferies conferences in June 2026. The company aims to update stakeholders on its direction and industry trends, with webcasts available for those unable to attend.
May 07, 2026 Charles River Laboratories Reports Mixed Results in First Quarter of 2026 Charles River Laboratories reported a slight revenue increase of 1.2% in Q1 2026, but faced profitability challenges with a GAAP net loss of $14.8 million. The company aims to enhance client experience and focus on core competencies to drive future growth.
April 30, 2026 Charles River Laboratories Unveils Innovative Rat In Vitro Fertility Services Charles River Laboratories has introduced advanced rat in vitro fertility services to speed up drug development in key therapeutic areas. This innovative approach reduces breeding bottlenecks and enhances research efficiency, allowing for quicker and more consistent outcomes.
April 21, 2026 Charles River Laboratories Unveils Effective Use of Virtual Control Groups in Toxicology Charles River Laboratories reveals that Virtual Control Groups (VCGs) maintain scientific rigor while reducing animal use in toxicology studies. Their analysis shows a 100% concordance in key findings, promoting ethical research through innovative methodologies and collaboration.
April 16, 2026 Charles River Laboratories Prepares for First-Quarter Earnings Release Charles River Laboratories will announce its first-quarter financial results on May 7, 2026, accompanied by a conference call at 8:30 a.m. ET. Investors are eager for insights into the company's performance and strategic direction in the life sciences sector.
April 09, 2026 Charles River Laboratories Partners with the American Heart Association to Promote Cardiovascular Health Charles River Laboratories collaborates with the American Heart Association to enhance cardiovascular health awareness and community initiatives. This partnership aims to combat heart disease, focusing on education and prevention, especially through the Heart of Boston campaign.
March 02, 2026 Charles River Laboratories Announces Upcoming Presentations at Key Investor Conferences Charles River Laboratories will participate in two key investor conferences in March 2026, focusing on strategic initiatives and industry trends. The company aims to engage stakeholders and provide insights into its developments through live webcasts.
February 25, 2026 Charles River Laboratories Announces Strategic Divestitures to Enhance Portfolio Charles River Laboratories has announced the divestiture of its CDMO and Cell Solutions businesses and certain European Discovery Services assets to enhance operational focus and shareholder value. The transactions, valued at over $200 million, are expected to close in Q2 2026 and will impact the company's financial guidance for the year.
February 18, 2026 Charles River Laboratories Enhances Leadership Team with Key Executive Appointments Charles River Laboratories has appointed Glenn Coleman as CFO and Kerry Dailey as Chief Legal Officer, aiming to bolster its leadership for future growth. These strategic appointments reflect the company's commitment to operational excellence in the life sciences sector.
February 18, 2026 Charles River Laboratories Reports Fourth-Quarter and Full-Year 2025 Results: Guidance for 2026 Announced Charles River Laboratories reported a slight decline in Q4 2025 revenue and a significant net loss, reflecting challenges in the biopharmaceutical sector. The company provided cautious guidance for 2026, forecasting potential organic revenue growth in the latter half of the year, driven by strategic initiatives and improved market performance.
February 18, 2026 Charles River Laboratories Releases 2025 Annual Report: A Year of Challenges and Strategic Evolution Charles River Laboratories' 2025 annual report reveals a slight revenue decline to $4.02 billion, driven by challenges in its Discovery and Safety Assessment segment. Despite setbacks, growth in the Research Models and Services segment and strategic acquisitions signal the company's resilience and commitment to operational efficiency.
January 21, 2026 Charles River Laboratories to Release Q4 2025 Earnings and 2026 Guidance Charles River Laboratories will release its Q4 2025 earnings on February 18, 2026, along with guidance for 2026. A conference call will follow to discuss the results and future outlook, making it a key event for investors.
January 21, 2026 Charles River Laboratories Teams Up with Gazi University for Gene Therapy Manufacturing Charles River Laboratories has partnered with Gazi University to enhance gene therapy manufacturing, particularly for rare diseases. This collaboration aims to provide essential plasmid DNA for research and therapy development, showcasing the importance of academic and commercial synergy in advancing healthcare.
January 12, 2026 Charles River Laboratories Unveils Strategic Acquisitions and Leadership Changes Charles River Laboratories announced key acquisitions of K.F. and PathoQuest, aimed at enhancing their service capabilities and supply chain. The company appointed Dr. Namandjé N. Bumpus as Chief Scientific Officer and shared a positive outlook for 2026, emphasizing growth in the drug development sector.
January 08, 2026 Charles River Laboratories Announces Leadership Transition Amidst Strategic Growth Charles River Laboratories announces the retirement of CEO James C. Foster and appoints Birgit Girshick as the new CEO. Foster's legacy includes transformative growth, while Girshick aims to build on this foundation as the company navigates future challenges.
December 11, 2025 Charles River Laboratories Expands Support for Advanced Therapies with New Incubator Program Cohort Charles River Laboratories has launched the second cohort of its Cell & Gene Therapy Incubator Program, aimed at empowering early-stage biotech companies. The initiative provides resources and expertise to accelerate the development of transformative therapies, showcasing six innovative companies tackling critical healthcare challenges.
December 01, 2025 Charles River Laboratories to Showcase Strategic Vision at Evercore Healthcare Conference Charles River Laboratories will present at the Evercore Healthcare Conference on December 3, 2025, discussing their strategic focus, recent developments, and market trends. The event will be accessible via a live webcast for interested stakeholders.
November 24, 2025 Investigation Launched into Charles River Laboratories by Kahn Swick & Foti, LLC Kahn Swick & Foti has initiated an investigation into Charles River Laboratories amid allegations of compliance failures and fiduciary breaches. The inquiry follows troubling disclosures about a DOJ subpoena related to illegal primate imports, which may affect the company's earnings and raise questions about leadership accountability.
November 17, 2025 Charles River Laboratories Set to Present at Jefferies Global Healthcare Conference Charles River Laboratories will present at the Jefferies Global Healthcare Conference on November 18, 2025. The event will highlight the company's strategic focus and recent developments in the healthcare sector, with a live webcast available for those unable to attend.
November 05, 2025 Charles River Laboratories Outlines Strategic Vision for Long-Term Growth Charles River Laboratories outlines its strategic vision for long-term growth, focusing on enhancing its scientific portfolio, streamlining operations, and disciplined capital deployment. Key initiatives include targeted investments in bioanalysis and geographic expansion, alongside divesting underperforming businesses for improved financial performance.
November 05, 2025 Charles River Laboratories Reports Third-Quarter 2025 Results: Steady Demand Amid Revenue Declines Charles River Laboratories' Q3 2025 results show a 0.5% revenue decline to $1.00 billion, despite improved operating margins. The firm maintains stable demand and updates financial guidance, projecting less revenue decrease than previously expected.
November 05, 2025 Charles River Laboratories Reports Q3 2025 Results: A Mixed Bag Amid Strategic Changes Charles River Laboratories reported a slight revenue decline in Q3 2025 due to cautious client spending. Despite challenges in some segments, growth in Research Models provides a positive outlook. The company plans strategic reviews to adapt to market conditions.
October 27, 2025 Investigation Launched into Charles River Laboratories Amid Legal Challenges Charles River Laboratories faces scrutiny from former Louisiana Attorney General Charles C. Foti, Jr. amid a DOJ investigation and a securities class action lawsuit. The outcomes could significantly impact the company's management and financial stability, prompting KSF to seek shareholder input.
October 24, 2025 Charles River Laboratories Under Scrutiny: Shareholder Rights Firm Investigates Potential Breaches Halper Sadeh LLC is investigating potential breaches of fiduciary duty by Charles River Laboratories' management, alarming shareholders. The firm urges investors to explore their rights and potential actions to safeguard their interests.
October 22, 2025 Charles River Laboratories Partners with The Francis Crick Institute to Advance Antibody-Drug Conjugate Development Charles River Laboratories has partnered with The Francis Crick Institute to enhance the development of Antibody-Drug Conjugates (ADCs). This collaboration aims to streamline the entire ADC lifecycle and leverage innovative techniques for improved safety and efficacy, ultimately delivering targeted therapies faster to patients.
October 20, 2025 Charles River Laboratories and X-Chem Join Forces to Revolutionize Hit Identification in Drug Discovery Charles River Laboratories has partnered with X-Chem to enhance hit identification in drug discovery. By integrating X-Chem's DEL platform with Charles River's expertise, they aim to accelerate the development of new therapeutics for biopharmaceutical clients.
October 15, 2025 Charles River Laboratories Announces Strategic Initiative to Drive Alternative Method Innovation Charles River Laboratories has established a Scientific Advisory Board to drive the innovation of New Approach Methodologies (NAMs) in drug development. This initiative aims to enhance therapeutic efficacy while minimizing animal testing, marking a pivotal shift in research practices.
October 14, 2025 Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release Charles River Laboratories has scheduled its third-quarter 2025 earnings release for November 5, alongside a conference call at 9:00 a.m. ET. This event aims to provide stakeholders with insights into the company's financial performance and strategic initiatives.
October 08, 2025 Charles River Laboratories and Toxys Join Forces for Innovative Developmental Toxicity Testing Charles River Laboratories and Toxys have partnered to enhance developmental toxicity testing using Toxys’ ReproTracker® technology. This collaboration aims to provide rapid, reliable assessments while reducing reliance on animal testing, aligning with ethical research practices.
August 06, 2025 Charles River Laboratories Reports Q2 2025 Financial Results: A Mixed Bag Amid Strategic Adjustments Charles River Laboratories reported modest revenue growth of 0.6% for Q2 2025, though net income and operating income saw significant declines. The company is implementing strategic restructuring to address challenges, particularly in the Discovery and Safety Assessment segment, amid a cautious client spending environment.
May 13, 2025 Charles River Laboratories to Showcase Strategic Vision at Bank of America Health Care Conference Charles River Laboratories will present at the Bank of America 2025 Health Care Conference, discussing its strategic focus and recent business developments. The live webcast will allow stakeholders to gain insights into the company's future directions.
May 07, 2025 Charles River Laboratories Announces Governance Overhaul and Strategic Review Charles River Laboratories is restructuring its Board of Directors and initiating a strategic review to improve long-term shareholder value. The changes include new board members and collaboration with Elliott Investment Management to explore growth opportunities.
May 07, 2025 Charles River Laboratories Reports Mixed Results for Q1 2025 Charles River Laboratories reported a revenue decline of 2.7% in Q1 2025, with significant drops in GAAP operating margins and net income. Despite challenges, the company shows signs of demand stabilization, particularly in the Discovery and Safety Assessment segment, leading to a cautious optimism for future growth.
May 07, 2025 Charles River Laboratories International Inc. Reports Q1 2025 Results: Challenges and Strategic Adjustments Charles River Laboratories reported a 2.7% revenue decline in Q1 2025 due to client spending cuts and restructuring costs. The company is implementing strategic adjustments to enhance efficiency and cost savings amid ongoing market challenges.
April 29, 2025 Charles River Laboratories Launches Inaugural Advanced Therapy Incubator Program Charles River Laboratories has launched its first Charles River Incubator Program (CIP) to support early-stage biotech innovators in developing advanced therapies. The inaugural cohort features six companies focused on groundbreaking technologies and life-saving treatments, highlighting the importance of incubators in the biotech ecosystem.
April 22, 2025 Charles River Laboratories Advances Oncology Research with Innovative Technologies Charles River Laboratories is enhancing oncology research with new technologies like PDX-derived tumoroids and immune-mediated assays. Their collaboration with Cypre and commitment to pediatric oncology highlight their leadership in developing effective cancer therapies.
April 15, 2025 Charles River Laboratories Prepares for First Quarter 2025 Earnings Release Charles River Laboratories is set to release its Q1 2025 earnings on May 7th, followed by a conference call to discuss performance and future strategies. Investors can access a live webcast for updates.
March 25, 2025 Charles River Laboratories and Valo Health Make Strides in Lupus Treatment with AI-Driven Discovery Charles River Laboratories and Valo Health have made significant strides in lupus treatment by identifying a potential therapy using the AI platform Logica®. This collaboration enhances drug discovery processes, marking a hopeful advancement for those suffering from autoimmune diseases.
March 11, 2025 Charles River Laboratories Set to Present at Barclays Global Healthcare Conference Charles River Laboratories will present at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025. The presentation will cover strategic initiatives, recent developments, and industry trends, showcasing the company's role in advancing pharmaceutical research.
February 25, 2025 Charles River Laboratories Partners with Singapore General Hospital to Advance Cancer Therapeutics Charles River Laboratories has partnered with Singapore General Hospital to advance cancer therapeutics using CGMP-compliant cell banking and next-generation sequencing for CAR T-cell development. This collaboration aims to improve cancer treatment capabilities while adhering to strict regulatory standards.
February 19, 2025 Charles River Laboratories International Inc. 2024 Annual Report: A Year of Resilience Amid Challenges Charles River Laboratories' 2024 annual report reveals a decline in revenue and net income due to market challenges. Despite this, the company is focusing on strategic acquisitions and partnerships to enhance its position and drive future growth in the biopharmaceutical industry.
February 19, 2025 Charles River Laboratories Reports Q4 and Full-Year 2024 Results, Eyes 2025 with Caution Charles River Laboratories reported a 1.1% revenue decline in Q4 2024, impacted by various market factors. Despite challenges, the company anticipates careful growth strategies for 2025, projecting further revenue declines and managing operational efficiencies.
February 16, 2025 SWOT Analysis of Charles River Laboratories International Inc. in 2025 This SWOT analysis details Charles River Laboratories in 2025, highlighting its strengths like market leadership and regulatory expertise, weaknesses such as high operational costs, opportunities in emerging markets, and threats from competition and legal challenges. The company is poised for growth by leveraging innovation and strategic partnerships.
February 11, 2025 Charles River Laboratories and Deciphex Strengthen Global Partnership to Enhance Digital Pathology Solutions Charles River Laboratories is expanding its collaboration with Deciphex to integrate advanced AI solutions in digital pathology. This partnership aims to enhance image management and streamline workflows in toxicologic pathology, ultimately accelerating drug development and improving patient safety.
November 06, 2024 Charles River Laboratories Reports Q3 2024 Financial Results: Navigating Challenges in a Cautious Market Charles River Laboratories reported mixed Q3 2024 financial results, with revenue decreasing by 1.6% and operating income down 18.3%. Despite these challenges, the company is adapting through strategic initiatives and maintaining strong cash flow.
August 07, 2024 Charles River Laboratories Reports Q2 2024 Results: Navigating Challenges Amidst Strategic Growth Charles River Laboratories reported a revenue decline of 3.2% in Q2 2024, reflecting cautious client spending. Despite challenges, the company is investing in innovation and restructuring for future growth.
May 09, 2024 Charles River Laboratories Reports Q1 2024: Analyzing Financial Performance Amidst Market Dynamics Charles River Laboratories reported a 1.7% revenue decrease in Q1 2024, driven by challenges in its Discovery and Safety Assessment segment. Despite this, the company showed strong cash flow and made strategic acquisitions to enhance its market position.